Results 131 to 140 of about 154,795 (245)

The use of diabetes technology under aviation conditions: A systematic review of human and in‐vitro studies and future considerations

Diabetic Medicine, EarlyView.
Abstract Background Despite advancements in diabetes management technologies, restrictions on insulin‐treated pilots persist, underscoring the need to evaluate the safety, efficacy and performance of these technologies in aviation settings. This systematic review aims to summarize the available evidence on the performance, safety and effectiveness of ...
Renald Meçani, Taulant Muka, Monika Cigler, Silvia Basta, Omaima El‐Hakouni, Petra M. Baumann, David Sanchez, Mikkel Thor Olsen, Chantal Mathieu, Thomas R. Pieber, Gerd Koehler, Julia K. Mader   +11 more
wiley   +1 more source

Psychological Resilience in Individuals with Type 2 Diabetes Mellitus in Jordan Is Associated with Insomnia Severity: A Cross-Sectional Analysis. [PDF]

J Clin Med
Gammoh O, Alsous MM, Gammoh H, Aljabali AAA, Abu Alshaik H, Alrtemat R, Al-Ameri M, AlNsour AM, Farraj R, Ireifij A, Alsharif AA, Alsaleh NA.   +11 more
europepmc   +1 more source

Prevalence and outcomes of DKA in type 1 and type 2 DM patients treated and not treated with SGLT‐2 inhibitors

Diabetic Medicine, EarlyView.
Abstract Aim To compare the clinical characteristics, biochemical presentation, and short‐ and long‐term outcomes of DKA in hospitalized adults with T1DM and T2DM, including the impact of SGLT2 inhibitor therapy. Methods A retrospective cohort of 2283 adults (838 with T1DM; 1445 with T2DM) hospitalized with DKA between 2013 and 2023 across Clalit ...
Elena Chertok Shacham, Sireen Sharif, Rageh Tatoor, Snait Ayalon   +3 more
wiley   +1 more source

Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Despite intensive lipid‐lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This risk is amplified in type 2 diabetes mellitus (T2DM), where a pro‐inflammatory milieu accelerates atherogenesis. Monocyte‐derived macrophages (MDMs)
J. K. Ward, M. U. Shah, K. Lee, P. E. Squires, C. E. Hills   +4 more
wiley   +1 more source

Reallocating morning physical activity to later‐day activity and its association with type 2 diabetes incidence: The Maastricht Study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The timing of physical activity may influence metabolic health through interactions with circadian rhythms, yet its role in type 2 diabetes mellitus (T2DM) development is unclear. We investigated associations between time‐of‐day‐specific physical activity and incident T2DM, and whether theoretically reallocating activity from morning to ...
Marvin Y. Chong, Simone J. P. M. Eussen, Jeroen H. P. M. van der Velde, Bastiaan E. de Galan, Hans H. C. M. Savelberg, Hans Bosma, Martijn J. L. Bours, Matty P. Weijenberg, Annemarie Koster   +8 more
wiley   +1 more source

Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances. [PDF]

Front Endocrinol (Lausanne)
Zhu B.
europepmc   +1 more source

Population‐based cohort validation and replication reveals limited generalizability of cluster‐based MASLD subtypes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims MASLD, defined as a steatotic liver disease in the presence of one or more cardiometabolic risk factors and the absence of harmful alcohol intake, exhibits substantial heterogeneity complicating risk stratification. A prior clustering model proposed liver‐specific and cardiometabolic subtypes, yet its generalizability and prognostic ...
Junjie Wu, Weiwei Xu, Guyu Zeng, Junfeng Wang   +3 more
wiley   +1 more source

The shared biomarkers and molecular mechanisms of systemic lupus erythematosus and type 2 diabetes. [PDF]

PLoS One
Yang D, Zhang Y, Ji L, Wu J, Yang F.
europepmc   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Perceived risk of type 2 diabetes mellitus: predictors of perceived susceptibility among young adults in Jordan. [PDF]

Front Public Health
Alkhaldi S, Taha H, BaniMustafa M, Al-Shimi R, AlSamhori J, Alshyyab M.   +5 more
europepmc   +1 more source